Vycor Medical, Inc. Reports First Quarter 2012 Results
May 16 2012 - 9:00AM
Marketwired
Vycor Medical, Inc. ("Vycor") (OTCBB: VYCO) yesterday reported
first quarter 2012 revenue of $432,601, a 198% increase on the
$145,122 for the first quarter of 2011. The Vycor Medical division
generated revenue of $321,781, a 222% increase on 2011, and
NovaVision generated revenue of $110,820, a 145% increase,
including a maiden contribution from Sight Science.
Gross profit for the first quarter of 2012 was $353,179 compared
to $122,749 in 2011. The overall group margin was slightly lower at
82% in 2012 compared to 85% in 2011.
Total Operating Expenses was $1,113,127 for the first quarter of
2012, a slight increase over $1,034,528 for 2011. The Net Loss was
$783,430, a reduction over the net loss of $935,700 reported for
2011.
Group Highlights for first quarter
2012
The first quarter of 2012 saw Vycor continue its momentum with a
number of new developments:
- Acquisition of Sight Science Limited (closed January 4, 2012),
a highly complementary business for NovaVision. The combination of
the therapies, technologies and knowhow of NovaVision and Sight
Science is a key element for the development and growth of
NovaVision in the future.
- Grant of registration for VBAS in Japan, with an initial order
being placed in the first quarter of 2012 and the placing of a
second order for China.
- Growth in VBAS's US hospital approvals with 12 new hospitals
coming on stream in the first quarter of 2012.
- Addition of Prof. Dr. Josef Zihl to the NovaVision Scientific
Advisory Board. Prof. Zihl is research group leader and Head of the
outpatient clinic for neuropsychology at the Max Planck Institute
of Psychiatry in Munich.
Additional Information More detailed
information on the Company and its first quarter results can be
found in its quarterly report on Form 10-Q for the three months
ended March 31, 2012 and its annual report on Form 10-K for the
year ended December 31, 2011.
About Vycor Medical, Inc. With corporate
headquarters in Boca Raton, FL, Vycor Medical, Inc. (OTCBB: VYCO)
is a medical device company committed to making neurological brain,
spinal and other surgical procedures safer and more effective. The
company's flagship, Patent Pending ViewSite™ Surgical Access
Systems represent an exciting new minimally invasive access and
retraction system that holds the potential for speedier, safer and
more economical brain, spinal and other surgeries and a quicker
patient discharge. Vycor's innovative medical instruments are
designed to optimize neurosurgical site access, reduce patient
risk, accelerate recovery, and add tangible value to the
professional medical community. Vycor is ISO 13485:2003 compliant,
has FDA 510(K) clearance for brain and spine surgeries, and CE
Marking and HPB licensing in Canada.
Vycor Medical's subsidiary, NovaVision, Inc., researches,
develops and provides science-driven vision-based neurostimulation
therapy and other medical technologies that help to improve sight
in patients with neurological vision impairments. The company's
proprietary, Visual Restoration Therapy (VRT) platform is
clinically supported to improve lost vision resulting from stroke,
traumatic brain injury ("TBI"), or other acquired brain injury, and
has been 510(K) cleared to be marketed in the US by the FDA. VRT
can be prescribed by any ophthalmologist, optometrist, neurologist
or physiatrist. NovaVision, through its subsidiary Sight Science,
also provides Neuro-Eye Therapy (NeET), aimed at increasing visual
sensitivity deep within the field defect. NovaVision also provides
a fully portable and ADA-compliant Head Mounted Perimeter (HMP™)
which aids in the detection and measurement of visual field
deficits
For the latest information on the company, including media and
other coverage, and to learn more, please go online at
www.vycormedical.com or www.novavision.com.
Safe Harbor Statement
Information in this document constitute
forward-looking statements or statements which may be deemed or
construed to be forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. The words
"forecast," "anticipate," "estimate," "project," "intend,"
"expect," "should," "believe," and similar expressions are intended
to identify forward-looking statements. These forward-looking
statements involve, and are subject to known and unknown risks,
uncertainties and other factors which could cause Vycor Medical's
actual results, performance (financial or operating) or
achievements to differ from the future results, performance
(financial or operating) or achievements expressed or implied by
such forward-looking statements. The risks, uncertainties and other
factors are more fully discussed in Vycor Medical's filings with
the U.S. Securities and Exchange Commission. All forward-looking
statements attributable to Vycor Medical herein are expressly
qualified in their entirety by the above-mentioned cautionary
statement. Vycor Medical disclaims any obligation to update
forward-looking statements contained in this estimate, except as
may be required by law.
Lenny Sorin Vycor Medical, Inc. 561-558-2000 Email Contact
Vycor Medical (QB) (USOTC:VYCO)
Historical Stock Chart
From Apr 2024 to May 2024
Vycor Medical (QB) (USOTC:VYCO)
Historical Stock Chart
From May 2023 to May 2024